Genmab — Juni 2017
-
The clonoSEQ
Assay is a highly accurate and sensitive method for detecting and quantifying MRD, or measurable residual disease, in lymphoid malignancies. MRD refers to the small number of cancer cells that can remain in a patient’s body after treatment and may eventually cause recurrence of the disease. -
Desværre er der ikke mange danske analytikere, der er i stand til at dissekere tallene - receptdata fra maj var særdeles robuste, men det kræver vist både en måned med ekstra mange arbejdsdage og impact fra en større labeludvidelse inden de kan se den underliggende udvikling
-
de kunne ikke ramme en ladeport, om den så faldt ned over dem
-
har der været linket til denne? http://penge.borsen.dk/artikel/1/347019/analytiker_om_darzalex-strategi_det_skal_vaere_umuligt_at_undgaa_kraeftmidlet.html
-
As other sectors stumble, health care stocks are finally hitting new all-time highs again after 2 long years - https://lyonssharepro.com/2017/06/this-sector-getting-healthy-just-in-time/
-
ærgerligt tidspunkt, at vi fik alle de gode nyheder i GEN...
-
Genmab is
now slowly reacting
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind